Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 8Stomach Neoplasms 6Uterine Cervical Neoplasms 2Non-Muscle Invasive Bladder Neoplasms 2Carcinoma, Transitional Cell 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Solid Tumor 1Prostatic Neoplasms 1Ovarian Neoplasms 1Ovarian Cancer Recurrent 1Metastatic HER2 Positive Gastroesophageal Junction Cancer 1Lung Neoplasms 1High-risk Non-muscle Invasive Bladder Cancer 1HER2-positive Metastatic Breast Cancer 1HER2-low Breast Cancer 1Castration-resistant Prostate Cancer 1Advanced Breast Cancer 1

Interventions

pembrolizumab 49Carboplatin 44Magnetic Resonance Spectroscopy 40Specimen Handling 39Pemetrexed 34Cisplatin 25Blood Specimen Collection 25durvalumab 17Paclitaxel 16osimertinib 15Radiotherapy 15Radiosurgery 15Bevacizumab 15Gemcitabine 14atezolizumab 13Nivolumab 13Biopsy 13Drug Therapy 12Standard of Care 10Practice Guidelines as Topic 10Immunoglobulin G 10Docetaxel 10130-nm albumin-bound paclitaxel 10X-Rays 9Taxes 9Educational Status 9Disulfides 9tislelizumab 8Etoposide 8Cetuximab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Lung Neoplasms × disitamab vedotin × Clear all
NCT06749860 2024-12-27

Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression

Shanghai Pulmonary Hospital, Shanghai, China

Phase 2 Recruiting
58 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡